Literature DB >> 18516748

[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia].

C Ruiz Huete1, P E Bermejo.   

Abstract

INTRODUCTION: Botulinum toxin type A has been used in a wide range of neurological diseases such as migraine, cervical dystonia, spasticity or tics. However, the use of this drug in the treatment of neuropathic pain is still uncommon despite the fact that more and more cases supporting its role as an alternative treatment are emerging in the literature. CASE REPORT: Herein, we report a case of an 83 year old woman who suffered from severe pain with neuropathic characteristics due to postherpetic neuralgia which was refractory to different conventional therapies. The neuropathic pain was dramatically improved by multiple botulinum toxin type A injections and the analgesia lasted 2 months. Treatment was well tolerated and there were no side effects.
CONCLUSIONS: Using botulinum toxin has been effective and well tolerated in the treatment of postherpetic neuralgia in our patient. Despite the fact that its action mechanisms is still unknown, we consider that botulinum neurotoxin may be an alternative treatment in relieving refractory neuropathic pain and that controlled studies are needed to study this possibility.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18516748

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  9 in total

Review 1.  [Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].

Authors:  L Halb; B J Amann; H Bornemann-Cimenti
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

2.  Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior.

Authors:  Marc J Marino; Tetsuji Terashima; Joanne J Steinauer; Kelly A Eddinger; Tony L Yaksh; Qinghao Xu
Journal:  Pain       Date:  2013-12-11       Impact factor: 6.961

3.  [Effect of botulinum toxin type B on residual limb sweating and pain. Is there a chance for indirect phantom pain reduction by improved prosthesis use?].

Authors:  K-U Kern; M Kohl; U Seifert; T Schlereth
Journal:  Schmerz       Date:  2012-04       Impact factor: 1.107

Review 4.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

5.  Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.

Authors:  Roshni Ramachandran; Carmen Lam; Tony L Yaksh
Journal:  Neurobiol Dis       Date:  2015-05-06       Impact factor: 5.996

6.  The efficacy of intradermal injection of botulinum toxin in patients with post-herpetic neuralgia.

Authors:  M R Emad; M Emad; P Taheri
Journal:  Iran Red Crescent Med J       Date:  2011-05-01       Impact factor: 0.611

7.  Treatment of Morton neuroma with botulinum toxin A: a pilot study.

Authors:  José M Climent; Francisco Mondéjar-Gómez; Carmen Rodríguez-Ruiz; Ismael Díaz-Llopis; Diego Gómez-Gallego; Patricia Martín-Medina
Journal:  Clin Drug Investig       Date:  2013-07       Impact factor: 2.859

8.  Complications of varicella zoster virus reactivation.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.972

Review 9.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.